Hims Hers Health is trading 4.7% up at $28.67 in a rebound alongside a 1.90% healthcare-sector gain supported by positive cancer-vaccine trial news.
- Shares fell 4.26% to $27.39 on August 18.
- Company-specific sentiment remains pressured by the recent second-quarter earnings loss and margin compression from branded weight-loss drugs.
- No new August 19 announcement was found.